ÐÇ¿ÕÓéÀÖ¹ÙÍø

October 2024

• Jones CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, Francis L, Grevendonk J, et al. Routine Vaccination Coverage — Worldwide, 2023 MMWR. 2024 / 73(43);978–84.
  • This report presents trends in World Health Organization (WHO) and UNICEF routine vaccination coverage estimates through 2023 across the 194 WHO member countries...
• Robinson M, Crain J, Kendall B, Alexander V, Diskin E, Saady D, et al. Statewide Outbreak of Neisseria meningitidis Serogroup Y, Sequence Type 1466 — Virginia, 2022–2024 MMWR. 2024 / 73(43);973–7.
  • Occurrence of meningococcal disease outbreaks in populations without well-defined risk groups might prompt exploration of novel control strategies, such as selective vaccination of close contacts...
• Bell J, Meng L, Barbre K, Wong E, Lape-Newman B, Koech W, et al. Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel — National Healthcare Safety Network, United States, 2023–24 Respiratory Virus Season MMWR. 2024 / 73(43);966–72.
  • Respiratory viral diseases pose risks for health care personnel in U.S. health care settings, and vaccination is an effective strategy for maintaining a healthy workforce and improving health care system resiliency...
• Sun J, Zhang Y, Zhou S, Song Y, Zhang S, Zhu J, et al. Laboratory-Confirmed Influenza Hospitalizations During Pregnancy or the Early Postpartum Period — Suzhou City, Jiangsu Province, China, 2018–2023 MMWR. 2024 / 73(43);958–64.
  • Increasing vaccination coverage among pregnant women can reduce influenza-associated morbidity...

• Ma KC, Castro J, Lambrou AS, Rose EB, Cook PW, Batra D, et al. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024 MMWR. 2024 / 73(42);938–45.
  • This report summarizes U.S. trends in variant proportion estimates during May 2023–September 2024, a period when SARS-CoV-2 lineages primarily comprised descendants of Omicron variants XBB and JN.1...

• Seither R, Yusuf OB, Dramann D, Calhoun K, Mugerwa-Kasujja A, Knighton CL, et al. Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2023–24 School Year MMWR. 2024 / 73(41);925–32.
  • Decreasing vaccination coverage and increasing exemptions increase the risk for vaccine-preventable disease outbreaks. Efforts by health departments, schools, and providers are needed to ensure that students begin school fully vaccinated...
• Namageyo-Funa A, Greene SA, Henderson E, Traoré MA, Shaukat S, Bigouette JP, et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2023–June 2024 MMWR. 2024 / 73(41);909–16
  • this report describes global polio outbreaks due to cVDPVs during January 2023–June 2024 and updates previous reports...

• Quinlan CM, Shah MM, DeSantis CE, Bertumen JB, Draper C, Ahmad FS, et al. Differences in COVID-19 Outpatient Antiviral Treatment Among Adults Aged ≥65 Years by Age Group — National Patient-Centered Clinical Research Network, United States, April 2022–September 2023 MMWR. 2024 / 73(39);876–82.
  • In addition to vaccination and access to early sensitive diagnostics such as polymerase chain reaction testing, COVID-19 treatment should be routinely discussed with older adults with mild or moderate COVID-19...
• Taylor CA, Patel K, Pham H, Kirley PD, Kawasaki B, Meek J, et al. COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥18 Years — COVID-NET, 12 States, October 2023–April 2024 MMWR. 2024 / 73(39);869–75.
  • Adults at increased risk for COVID-19–associated hospitalization should reduce their risk for severe COVID-19 by adopting measures to reduce risk for contracting COVID-19, receiving recommended COVID-19 vaccinations, and seeking prompt outpatient antiviral treatment after a positive SARS-CoV-2 test result...
• Zeno EE, Nogareda F, Regan A, Couto P, Rondy M, Jara J, et al. Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization — REVELAC-i Network, Five South American Countries, March–July 2024 MMWR. 2024 / 73(39);861–8.
  • ÐÇ¿ÕÓéÀÖ¹ÙÍø recommends that all eligible persons aged ≥6 months receive seasonal influenza vaccine. Early antiviral treatment can complement vaccination to protect against severe influenza-related morbidity...

September 2024

• Tippins A, Boyd EM, Coy KC, Mutamba G, Kriss JL. Vaccination Coverage by Age 24 Months Among Children Born During 2017–2021 — U.S.-Affiliated Pacific Islands MMWR. 2024 / 73(38);854–9.
  • This report describes vaccination coverage by age 24 months in five of the six USAPI jurisdictions among children born during 2017–2021...
• Hill HA, Yankey D, Elam-Evans LD, Mu Y, Chen M, Peacock G, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023 MMWR. 2024 / 73(38);844–53.
  • This report assesses trends in vaccination coverage by year of birth and disparities in coverage by sociodemographic characteristics...
• Razzaghi H, Garacci E, Kahn KE, Lindley MC, Jones JM, Stokley S, et al. Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months — United States, April 2024 MMWR. 2024 / 73(38);837–43.
  • This report provides estimates of RSV maternal vaccination coverage, receipt of nirsevimab by infants, and proportion of infants protected by either product in the United States during the 2023–24 RSV season...
• Havers FP, Whitaker M, Chatwani B, Patton ME, Taylor CA, Chai SJ, et al. COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months — COVID-NET, 12 States, October 2022–April 2024 MMWR. 2024 / 73(38);830–6.
  • COVID-19 can cause severe disease in infants aged <6 months; prevention should focus on ensuring that pregnant persons receive recommended COVID-19 vaccines to protect themselves and their young infants...

• Panagiotakopoulos L, Moulia DL, Godfrey M, Link-Gelles R, Roper L, Havers FP, et al. Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025 MMWR. 2024 / 73(37);819–24.
  • The 2024–2025 COVID-19 vaccines are recommended for all persons aged ≥6 months to target currently circulating SARS-CoV-2 strains and provide additional protection against severe COVID-19–associated illness and death...
• Collins JP, Loehr J, Chen WH, Clark M, Pinell-McNamara V, McNamara LA. Use of Haemophilus influenzae Type b–Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendations of the Advisory Committee on Immunization Practices ― United States, 2024 MMWR. 2024 / 73(36);799–802.
  • This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of Hib-containing vaccines among AI/AN infants and children...
• Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 MMWR. 2024 / 73(36);793–8.
  • This report summarizes the evidence considered by ACIP regarding the use of PCV21 for adults, highlighting considerations of immunogenicity, safety, and resource use...
• Mbaeyi C, ul Haq A, Safdar RM, Khan Z, Corkum M, Henderson E, et al. Progress Toward Poliomyelitis Eradication — Pakistan, January 2023–June 2024 MMWR. 2024 / 73(36);788–92.
  • This report describes Pakistan’s progress toward eliminating indigenous WPV1 transmission during January 2023–June 2024...

August 2024

• Valier MR, Yankey D, Elam-Evans LD, Chen M, Hill HA, Mu Y, et al. Vital Signs: Trends and Disparities in Childhood Vaccination Coverage by Vaccines for Children Program Eligibility — National Immunization Survey-Child, United States, 2012–2022 MMWR. 2024 / 73(33);722-30.
  • This report 1) describes characteristics of children eligible for the VFC program; 2) examines trends in routine vaccination coverage among VFC-eligible children; and 3) identifies gaps in vaccination coverage among VFC-eligible children compared with children who are not VFC-eligible...
• Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 MMWR. 2024 / 73(32);696-702.
  • This report summarizes the evidence considered for these updated recommendations, including postlicensure data on vaccine effectiveness and safety, and provides clinical guidance for the use of RSV vaccines in adults aged ≥60 years...
• Zhou F, Jatlaoui TC, Leidner AJ, Carter RJ, Dong X, Santoli JM, et al. Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program — United States, 1994–2023 MMWR. 2024 / 73(31);682–5.
  • This report assessed and quantified the health benefits and economic impact of routine U.S. childhood immunizations among both VFC-eligible and non–VFC-eligible children born during 1994–2023...
• Tohme RA, Shadaker S, Adamia E, Khonelidze I, Stvilia K, Getia V, et al. Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015–April 2024 MMWR. 2024 / 73(30);660–6.
  • This report describes the progress made during April 2015–April 2024 toward achieving hepatitis B and hepatitis C elimination in Georgia...

July 2024

• Alleman MM, Sereno LS, Whittembury A, Li X, Contreras M, Pacis-Tirso C, Gonzalez MV, et al. Progress Toward Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Region of the Americas, 2012–2022 MMWR. 2024 / 73(29);648–55.
  • This report describes progress toward the elimination of MTCT of HBV infection in AMR during 2012–2022...
• Jones CE, Yusuf N, Ahmed B, Kassogue M, Wasley A, Kanu FA. Progress Toward Achieving and Sustaining Maternal and Neonatal Tetanus Elimination — Worldwide, 2000–2022 MMWR. 2024 / 73(28);614–21.
  • This report updates a previous report and describes progress toward MNTE during 2000–2022...

June 2024

• Mendes A, Mohamed GA, Derow M, Stehling-Ariza T, Mohamed A, Mengistu K, et al. Persistent Transmission of Circulating Vaccine-Derived Poliovirus — Somalia, January 2017–March 2024 MMWR. 2024 / 73(25);575–80.
  • This report describes the ongoing activities and challenges in interrupting transmission of cVDPV2 in Somalia from 2017 to the present, highlighting progress and identifying areas requiring focused intervention...
• Adegoke OJ, Rachlin A, Porter AM, Katsande R, Kubenga S, Potter R, et al. Migration from Epi Info to District Health Information Software 2 for Vaccine-Preventable Disease Surveillance — World Health Organization African Region, 2019–2023 MMWR. 2024 / 73(23);529–33.
  • High-quality vaccine-preventable disease (VPD) surveillance data are critical for timely outbreak detection and response...
• Vachon MS, Barret A, Lucidarme J, Neatherlin J, Rubis AB, Howie RL, et al. Cases of Meningococcal Disease Associated with Travel to Saudi Arabia for Umrah Pilgrimage — United States, United Kingdom, and France, 2024 MMWR. 2024 / 73(22);514–6.
  • Pilgrims aged ≥1 year entering Saudi Arabia should have received a quadrivalent meningococcal (MenACWY) vaccine within the last 3–5 years (depending on vaccine type)...
• Berdahl CT, Krishnadasan A, Pathmarajah K, Moran GJ, Torres JR, Waxman M, et al. Mpox Surveillance Based on Rash Characteristics — 13 Emergency Departments, United States, June–December 2023 MMWR. 2024 / 73(22);507–13.
  • Clinicians should remain vigilant for monkeypox virus infections, particularly among GBMSM, and educate patients about the importance of risk reduction and JYNNEOS vaccination...

May 2024

• Garg S, Reed C, Davis CT, Uyeki TM, Behravesh CB, Kniss K, et al. Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Viruses in U.S. Dairy Cattle and Detection of Two Human Cases — United States, 2024 MMWR. 2024 / 73(21);501–5.
  • Activities implemented using a One Health approach to respond to this outbreak include monitoring for infections in exposed persons, conducting syndromic and laboratory surveillance, planning for epidemiologic investigations, and assessing performance of existing medical countermeasures including diagnostic tests, vaccines, and therapeutics...
• Hause AM, Moro PL, Baggs J, Zhang B, Marquez P, Melgar M, et al. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024 MMWR. 2024 / 73(21);489–94.
  • The Advisory Committee on Immunization Practices (ACIP) recommends adults aged ≥60 years may receive 1 dose of RSV vaccine...
• Graham KA, Arciuolo RJ, Matalka O, Isaac BM, Jean A, Majid N, et al. Varicella Outbreak Among Recent Arrivals to New York City, 2022–2024 MMWR. 2024 / 73(21);478–83.
  • This outbreak highlights the importance of limiting transmission by achieving and sustaining high varicella vaccination coverage and the need for rapid, large-scale vaccination efforts in light of ongoing importations and exposures in U.S. shelters and residential facilities...
• Tuttle A, Hughes CM, Dvorak M, Aeschleman L, Davidson W, Wilkins K, et al. Notes from the Field: Clade II Mpox Surveillance Update — United States, October 2023–April 2024 MMWR. 2024 / 73(20);474–6.
  • This report summarizes mpox surveillance data reported to ÐÇ¿ÕÓéÀÖ¹ÙÍø during October 1, 2023–April 30, 2024...
• Guagliardo SAJ, Kracalik I, Carter RJ, Braden C, Free R, Hamal M, et al. Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine — United States, May 2022–May 2024 MMWR. 2024 / 73(20);460–6.
  • This report corroborates other published findings indicating that MPXV infection in fully vaccinated U.S. persons is rare and less severe regardless of the route of vaccination...
• Geiger K, Stehling-Ariza T, Bigouette JP, Bennett SD, Burns CC, Quddus A, et al. Progress Toward Poliomyelitis Eradication — Worldwide, January 2022–December 2023 MMWR. 2024 / 73(19);441–6.
  • This report summarizes the ACIP recommendation for an additional dose of the updated COVID-19 vaccine for persons aged ≥65 years and the rationale, including evidence reviewed by the work group and presented to ACIP...
• McQuiston JH, Luce R, Kazadi DM, Bwangandu CN, Mbala-Kingebeni P, Anderson M, et al. U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo — United States, 2024 MMWR. 2024 / 73(19);435–40.
  • This report describes investigation of cases in DRC, ÐÇ¿ÕÓéÀÖ¹ÙÍø's support to DRC, and U.S. public health preparedness activities to date...
• Masters NB, Holmdahl I, Miller PB, Kumar CK, Herzog CM, DeJonge PM, et al. Real-Time Use of a Dynamic Model To Measure the Impact of Public Health Interventions on Measles Outbreak Size and Duration — Chicago, Illinois, 2024 MMWR. 2024 / 73(19);430–4.
  • Prompt mass vaccination and active case-finding likely substantially reduced the likelihood of a large measles outbreak in Chicago...
• Gressick K, Nham A, Filardo TD, Anderson K, Black SR, Boss K, et al. Measles Outbreak Associated with a Migrant Shelter — Chicago, Illinois, February–May 2024 MMWR. 2024 / 73(19);424–9.
  • Ensuring high measles vaccination coverage during an outbreak can control measles spread and prevent wider transmission...

April 2024

• Panagiotakopoulos L, Godfrey M, Moulia DL, Link-Gelles R, Taylor CA, Chatham-Stephens K, et al. Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 MMWR. 2024 / 73(16);377–81.
  • This report describes global polio immunization, surveillance activities, and poliovirus epidemiology during January 2022–December 2023, using data current as of April 10, 2024...
• Smith-Jeffcoat SE, Mellis AM, Grijalva CG, Talbot HK, Schmitz J, Lutrick K, et al. SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance — Respiratory Virus Transmission Network, November 2022–May 2023 MMWR. 2024 / 73(16);365–71.
  • Clinicians should consider RT-PCR testing for persons for whom antiviral treatment is recommended...
• Kallay R, Doshi RH, Muhoza P, Choi MJ, Legand A, Aberle-Grasse E, et al. Use of Ebola Vaccines — Worldwide, 2021–2023 MMWR. 2024 / 73(16);360–64.
  • This report describes the use of Ebola vaccines and the role of the stockpile developed and managed by the International Coordinating Group (ICG) on Vaccine Provision during 2021–2023...
• Collins JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, Campos-Outcalt D, Loehr J, et al. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023 MMWR. 2024 / 73(15);345–50.
  • This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-TT/MenB-FHbp...
• Franklin D, Barbre K, Rowe TA, Reses HE, Massey J, Meng L, et al. COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19–Associated Hospitalization Among Residents in Nursing Homes — National Healthcare Safety Network, United States, October 2023–February 2024 MMWR. 2024 / 73(15);339–44.
  • Ongoing surveillance for SARS-CoV-2 infections and COVID-19–associated hospitalizations in this population is necessary to develop and evaluate evidence-based interventions for protecting nursing home residents...
• Zambrano LD, Newhams MM, Simeone RM, Payne AB, Wu M, Orzel-Lockwood AO, et al. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents — United States, 2021–2023 MMWR. 2024 / 73(15);330–8.
  • These findings support existing recommendations that children and adolescents aged 5–18 years remain up to date with COVID-19 vaccination given low vaccination coverage and waning effectiveness over time against COVID-19–related hospitalizations...
• Liko J, Cieslak PR. Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine — Oregon, June 2021–December 2022 MMWR. 2024 / 73(14);317–20.
  • The data do not support an association of COVID-19 vaccination with sudden cardiac death among previously healthy young persons...
• Doshi RH, Nsasiirwe S, Dahlke M, Atagbaza A, Aluta OE, Tatsinkou AB, et al. COVID-19 Vaccination Coverage — World Health Organization African Region, 2021–2023 MMWR. 2024 / 73(14);307–11.
  • This report provides an update on the progress made in COVID-19 vaccination in the African Region during 2021–2023...
• Mathis AD, Raines K, Masters NB, Filardo TB, Kim G, Crooke SN, et al. Measles — United States, January 1, 2020–March 28, 2024 MMWR. 2024 / 73(14);295–300.
  • Enhanced efforts are needed to increase routine U.S. vaccination coverage, encourage vaccination before international travel, identify communities at risk for measles transmission, and rapidly investigate suspected measles cases to reduce cases and complications of measles...
• Roua EK, Nkenge J, Mattie AE. Olorukooba A, Vazquez M, Stokley S, et al. Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics — United States, September 1, 2022–September 30, 2023 MMWR. 2024 / 73(13);286–90.
  • FRPP partnerships were critical in ensuring access to bivalent COVID-19 vaccination services in the United States and could serve as a model to address vaccination services needs for routine vaccines and during future responses to vaccine-preventable disease emergencies...
• Kishore N, Krow-Lucal E, Diop OM, Jorba J, Avagnan T, Grabovac V, et al. Surveillance To Track Progress Toward Polio Eradication — Worldwide, 2022–2023 MMWR. 2024 / 73(13);278–85.
  • This report updates previous reports to describe polio surveillance performance during 2022–2023 in 28 priority countries (i.e., those deemed to be at high risk for poliovirus transmission because of ongoing surveillance gaps and vulnerability to poliovirus circulation)...

March 2024

• Link-Gelles R, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, et al. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024 MMWR. 2024 / 73(12);271–6.
  • All persons with immunocompromising conditions should receive updated COVID-19 vaccination and may get additional updated COVID-19 vaccine doses ≥2 months after the last recommended COVID-19 vaccine...
• Thomas CM, Hartley A, Schmitz A, Reid HD, Sullivan S, Huebner E, et al. Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels — United States, May 2022–April 2023 MMWR. 2024 / 73(12);260–4.
  • Any detection of measles virus should be immediately reported to public health agencies to determine appropriate public health response...
• Ruprecht A, Marin M, Strain AK, Harry K, Kenyon C. Notes from the Field: Expanded Laboratory Testing for Varicella — Minnesota, 2016–2023 MMWR. 2024 / 73(11);245–6.
  • Laboratory confirmation is important to guide clinical and public health management, understand varicella epidemiology, and evaluate vaccine effectiveness...
• Bemis K, Frias M, Giovanni S, Shackour T, Reid HD, Morgan J, et al. Notes from the Field: Measles Outbreak — Cook County, Illinois, October–November 2023 MMWR. 2024 / 73(10);229–230.
  • Two doses of appropriately spaced MMR vaccine are recommended for all children and other susceptible persons to prevent measles cases and outbreaks...
• Yousaf AR, Lindsey KN, Wu MJ, Shah AB, Free RJ, Simeone RM, et al. Notes from the Field: Multisystem Inflammatory Syndrome, Children MMWR. 2024 / 73(10);225–8.
  • This report describes 2023 MIS-C cases and compares them with cases reported earlier in the COVID-19 pandemic...

February 2024

• DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, et al. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024 MMWR. 2024 / 73(8);180–8.
  • These findings support ÐÇ¿ÕÓéÀÖ¹ÙÍø recommendations for updated 2023–2024 COVID-19 vaccination...
• Zhu S, Quint J, León TM, Sun M, Li NJ, Tenforde MW, et al. Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza — California, October 2023–January 2024 MMWR. 2024 / 73(8);175–9.
  • Mandatory reporting requirements of laboratory surveillance and vaccination data allow for early season VE estimates while seasonal influenza viruses are circulating...
• Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, et al. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States MMWR. 2024 / 73(8);168–74.
  • This report provides interim estimates of 2023–24 seasonal influenza vaccine effectiveness (VE) against laboratory-confirmed influenza for children, adolescents, and adults in the outpatient and inpatient settings from active and passive surveillance systems in 22 U.S. states...
• Musa N, Ghoniem A, Hsu CH, Mubarak S, Sume G, Sharifuzzaman M, et al. Progress Toward Measles Elimination — World Health Organization Eastern Mediterranean Region, 2019–2022 MMWR. 2024 / 73(7);139–44.
  • This report updates a previous report and describes progress toward measles elimination in EMR during 2019–2022...
• Qureshi NS, Villatoro AJ, Tran ND, Herrera SJ, Judge SP, Fang L, et al. Hepatitis A Exposure Response and Outbreak Prevention in a Large Urban Jail — Los Angeles County, California, May–July 2023 MMWR. 2024 / 73(6);131–4.
  • Identifying contacts promptly and using immunization and serology records to ensure rapid delivery of postexposure prophylactic vaccine can help prevent hepatitis A transmission during exposures among incarcerated populations...
• Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 MMWR. 2024 / 73(4);77–83.
  • This report provides early estimates of effectiveness of updated monovalent XBB.1.5 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and the first estimates of VE against symptomatic infection with the JN.1 lineage...

January 2024

• Leonard CM, Poortinga K, Nguyen E, Karan A, Kulkarni S, Cohen R, et al. Mpox Outbreak — Los Angeles County, California, May 4–August 17, 2023 MMWR. 2024 / 73(2);44–8.
  • This outbreak underscores the ongoing need for accessible mpox vaccination for persons at risk, particularly among young, Black or African American, and Hispanic or Latino persons, and persons living with HIV...
• Payne AB, Novosad S, Wiegand RE, Najdowski M, Gomes DJ, Wallace M, et al. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023 MMWR. 2024 / 73(1);16–23.
  • COVID-19 vaccines helped provide protection against COVID-19–related thromboembolic events...
• Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024 MMWR. 2024 / 73(1);11–5.
  • At its October 2023 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2024...
• Wodi AP, Murthy N, McNally V, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024 MMWR. 2024 / 73(1);6–10.
  • At its October 2023 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024...